文献速递外周动脉疾病

药物洗脱支架治疗严重肢体缺血膝下动脉病变的真实世界单中心经验

Use of drug-eluting stents in patients with critical limb ischemia and infrapopliteal arterial disease: a real-world single-center experience.
PubMed 文献 · J Vasc Surg · 2021-06-25

本研究回顾性分析107条严重肢体缺血患肢(98例患者,118处病变)使用依维莫司药物洗脱支架(Xience)的临床结局。术后1年主要不良肢体事件率为15%,主要不良事件率45%,1年一期通畅率57%,3年降至33%,无大截肢生存率3年61%。结论认为1年结果尚可,但劣于既往报道,尤其3年结果,需长期随访数据。

要点

  • 依维莫司DES治疗膝下动脉病变1年一期通畅率57%,3年降至33%。
  • 1年主要不良肢体事件率15%,主要不良事件率45%。
  • 3年无大截肢生存率61%,总体结果劣于既往报道。

核心结论

  • DES治疗膝下病变1年结局尚可,但劣于既往报道,尤其3年结局。
  • 需进一步长期随访数据。

研究设计与样本

  • 真实世界单中心回顾性分析,纳入107条严重肢体缺血患肢(98例患者,118处病变),均置入依维莫司DES(Xience)。
  • 分析术后早期结局、主要不良肢体事件(1年内踝上截肢或大干预)及主要不良事件(死亡、截肢、靶病变血栓或再干预)。
  • 采用Kaplan-Meier分析一期通畅率(超声)、无截肢率及无截肢生存率。

主要发现

  • 病变分布:胫前动脉33%,胫腓干28%,胫后动脉21%,腓动脉8%,胫腓干/胫后动脉5%,胫腓干/腓动脉4%,胫腓干/胫前动脉1%。
  • 平均病变长度41 mm,59%为完全闭塞(41%狭窄),平均随访18.5个月(范围1-70个月)。
  • 术后总并发症率11%(大截肢2%),死亡率2%;71%患者晚期症状改善至少一个Rutherford分级。
  • 30天和1年主要不良事件率分别为12%和45%;1年主要不良肢体事件率15%。
  • 总体一期通畅率42%;1、2、3年一期通畅率分别为57%、45%、33%。

临床怎么用

  • 依维莫司DES可用于膝下动脉病变的严重肢体缺血患者,但需关注1年及3年通畅率下降和不良事件风险。
  • 术后应密切随访,监测靶病变再狭窄和肢体不良事件。

局限性

  • 单中心真实世界回顾性设计,样本量有限(98例患者,107条患肢),可能存在选择偏倚。
  • 缺乏对照组,无法直接比较DES与其他治疗方式的疗效。
  • 随访时间不均(1-70个月),长期结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although no drug-eluting stent (DES) has been approved by the Food and Drug Administration to treat infrapopliteal arterial disease, several industry-sponsored trials have reported the outcomes with the use of paclitaxel or sirolimus DESs. To the best of our knowledge, only one study to date has reported on the use of everolimus DESs for infrapopliteal arterial disease. In the present study, we analyzed the clinical outcomes with everolimus DESs in our real-world, single-center experience. METHODS: A total of 107 limbs with critical limb threatening ischemia (98 patients; 118 lesions) treated with DESs (Xience; Abbott Vascular, Santa Clara, Calif) were analyzed. The postoperative early outcomes, major adverse limb events (above the ankle limb amputation or major intervention at 1 year), and major adverse events (death, amputation, target lesion thrombosis or reintervention) were analyzed. Kaplan-Meier analysis was used to estimate the primary patency rates (using duplex ultrasound), amputation-free rates, and amputation-free survival rates. RESULTS: Of the 118 lesions treated, 33% were in the anterior tibial artery, 28% were in the tibioperoneal (TP) artery, 21% were in the posterior tibial artery, 8% were in the peroneal artery, 5% were in the TP/posterior tibial artery, 4% were in the TP artery/PA, and 1% were in the TP/anterior tibial artery. The mean lesion length was 41 mm, and 59% were totally occluded (41% stenotic). The mean follow-up was 18.5 months (range, 1-70 months). The overall postoperative complication rate was 11% (2% major amputations), with 2% mortality. Late symptom improvement of one or more Rutherford category was obtained in 71%. The major adverse events rate at 30 days and 1 year was 12% and 45%, respectively. The major adverse limb events rate at 1 year was 15%. The overall primary patency rate was 42%. The primary patency rate at 1, 2, and 3 years was 57%, 45%, and 33%, respectively. The major amputation-free and overall amputation-free survival rates were 87%, 80%, and 77% and 76%, 65%, and 61% at 1, 2, and 3 years, respectively. CONCLUSIONS: The clinical outcomes after DES (Xience; Abbott Vascular) for infrapopliteal lesions were somewhat satisfactory at 1 year but inferior to the previously reported outcomes, especially at 3 years. Further data with long-term follow-up are needed.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. AbuRahma AF, Beasley M, Davis M, et al. Use of drug-eluting stents in patients with critical limb ischemia and infrapopliteal arterial disease: a real-world single-center experience. J Vasc Surg. 2021. PMID: 34182023. doi:10.1016/j.jvs.2021.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。